Dr. Daniel Spratt

Dr. Daniel Spratt, MD, is a board-certified, international expert in the management of prostate cancer. Dr. Spratt attended Vanderbilt University (Nashville, Tennessee) for his medical training and completed his Radiation Oncology residency at Memorial Sloan Kettering (New York, New York).

He joined the University of Michigan in 2015, where he developed a large NIH-funded translational and clinical research group and was founding co-Director of the Spine Oncology Program. Dr. Spratt received a number of awards in recognition for his teaching, mentorship, research and service during his time at University of Michigan. Furthermore, he was promoted to a tenured full professor faster than any other faculty member at the university, obtaining tenure in just five years following the completion of his training at Memorial Sloan Kettering. He served as the Vice Chair in the Department of Radiation Oncology and Chair of the Genitourinary Clinical Research Team until April 2021, when he joined UH and CWRU.

Dr. Spratt currently serves as chair of the Department of Radiation Oncology at University Hospitals Cleveland Medical Center, and he joined the faculty of Case Western Reserve University School of Medicine in 2021. He also holds the Vincent K. Smith Chair in Radiation Oncology. Dr. Spratt’s clinical expertise encompasses the management of genitourinary cancers (prostate, bladder, kidney, and testicular), metastasis-directed radiotherapy, and spine stereotactic body radiotherapy.

Dr. Spratt is an international expert in the management of prostate cancer and the development and validation of prognostic and predictive biomarkers. His research expertise centers on the development and validation of prognostic and predictive biomarkers used to personalize treatment of cancer patients while avoiding over- and under-treatment. Dr. Spratt has received federal funding from the NIH, Department of Defense, and numerous foundations for his research. He is the principal or co-principal investigator on over 10 institutional, national or multinational clinical trials, runs a National Institute of Health-funded translational lab, and has mentored over 40 students and faculty.

Dr. Spratt has published over 300 peer-reviewed manuscripts, including practice-changing work in the New England Journal of Medicine, JAMA, Lancet Oncology, JAMA Oncology and the Journal of Clinical Oncology. He serves as the Chair for NRG Oncology's Intact Prostate Cancer Subcommittee, and for the National Cancer Institute's Genitourinary Steering Committee. Dr. Spratt regularly receives invitations from all over the world to give lectures on the management and personalization of prostate cancer. Dr. Spratt’s primary professional goal is to create a world-class Department of Radiation Oncology that provides cutting edge personalized and compassionate care.